Sma – Therapy

Abstract

S46-S150 in ENDEAR), mean (SD) CHOP INTEND scores increased by + 5.1 (6.1; n = 11) points from baseline to Day 1058. Together, these results demonstrate the importance of early initiation of nusinersen treatment on longer-term motor function outcomes in individuals with SMA.